CYP4F18-Deficient Neutrophils Exhibit Increased Chemotaxis to Complement Component C5a

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Vaivoda, Rachel ^a   Vaine, Christine ^a   Boerstler, Cassandra ^b   Galloway, Kristy ^b   Christmas, Peter ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b RADFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A; CYTOCHROME P450; CYTOCHROME P450 4F18; DEXTRAN SULFATE; LEUKOTRIENE B4; MYELOPEROXIDASE; UNCLASSIFIED DRUG; CXCL1 CHEMOKINE; CXCL1 PROTEIN, MOUSE; CYP4F18 PROTEIN, MOUSE; CYTOCHROME P450 FAMILY 4; FORMYLPEPTIDE RECEPTOR; ISOENZYME; PEPTIDE; PEROXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL MIGRATION; COLITIS; CONTROLLED STUDY; DESENSITIZATION; DISEASE ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; NEUTROPHIL; PATHOLOGY; PRIMARY CELL CULTURE;

ANIMALS; BONE MARROW CELLS; CHEMOKINE CXCL1; CHEMOTAXIS, LEUKOCYTE; COLITIS; COMPLEMENT C5A; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROME P450 FAMILY 4; DEXTRAN SULFATE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; ISOENZYMES; LEUKOTRIENE B4; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; PEPTIDES; PEROXIDASE; PRIMARY CELL CULTURE; RECEPTORS, FORMYL PEPTIDE; WEIGHT LOSS;

EID: 84947447550     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/250456     Document Type: Article

References (33)

1. A. Kalsotra and H. W. Strobel, "CytochromeP450 4F subfamily: At the crossroads of eicosanoid and drug metabolism, " Pharmacology &Therapeutics, vol. 112, no. 3, pp. 589-611, 2006.
2. N. Flamand, P. Mancuso, C. H. C. Serezani, and T. G. Brock, "Leukotrienes: mediators that have been typecast as villains, " Cellular andMolecular Life Sciences, vol. 64, no. 19-20, pp. 2657-2670, 2007.
3. J. Z. Haeggström and C. D. Funk, "Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease, " Chemical Reviews, vol. 111, no. 10, pp. 5866-5896, 2011.
4. N. Sehgal, V. Agarwal, R. K. Valli et al. , "Cytochrome P4504f, a potential therapeutic target limiting neuroinflammation, " Biochemical Pharmacology, vol. 82, no. 1, pp. 53-64, 2011.
5. A. Kalsotra, L. Du, Y. Wang et al. , "Inflammation resolved by retinoid X receptor-mediated inactivation of leukotriene signaling pathways, " The FASEB Journal, vol. 22, no. 2, pp. 538-547, 2008.
6. L. Du, H. Yin, J. D. Morrow, H. W. Strobel, andD. S. Keeney, "20-Hydroxylation is the CYP-dependent and retinoid-inducible leukotriene B4 inactivation pathway in human and mouse skin cells, " Archives of Biochemistry and Biophysics, vol. 484, no. 1, pp. 80-86, 2009.
7. A. Ikehata, N. Hiwatashi, Y. Kinouchi, K. Ito, H. Yamazaki, and T. Toyota, "Leukotriene B4 omega-hydroxylase activity in polymorphonuclear leukocytes from patients with inflammatory bowel disease, " Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 49, no. 1, pp. 489-494, 1993.
8. A. Ikehata, N. Hiwatashi, Y. Kinouchi, H. Yamazaki, K. Ito, and T. Toyota, "Altered leukotriene B4 metabolism in colonic mucosa with inflammatory bowel disease, " Scandinavian Journal of Gastroenterology, vol. 30, no. 1, pp. 44-49, 1995.
9. C. R. Curley, A. J. Monsuur, M. C. Wapenaar, J. D. Rioux, and C. Wijmenga, "A functional candidate screen for coeliac disease genes, " European Journal of Human Genetics, vol. 14, no. 11, pp. 1215-1222, 2006.
10. I. Costea, D. R. Mack, D. Israel et al. , "Genes involved in the metabolism of poly-unsaturated fatty-Acids (PUFA) and risk for Crohns disease in children & young adults, " PLoS ONE, vol. 5, no. 12, Article ID e15672, 2010.
11. R. C. Murphy andM. A. Gijon, "Biosynthesis andmetabolism of leukotrienes, " Biochemical Journal, vol. 405, no. 3, pp. 379-395, 2007.
12. S. Shak and I. M. Goldstein, "Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes, "The Journal of Biological Chemistry, vol. 259, no. 16, pp. 10181-10187, 1984.
13. Y. Kikuta, E. Kusunose, and M. Kusunose, "Prostaglandin and leukotriene hydroxylases, " Prostaglandins & Other Lipid Mediators, vol. 68-69, pp. 345-362, 2002.
14. R. J. Soberman, T. W. Harper, R. C. Murphy, and K. F. Austen, "Identification and functional characterization of leukotriene B4 20-hydroxylase of human polymorphonucler leukocytes, " Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 2, pp. 536-541, 1985.
15. Y. Kikuta, E. Kusunose, K. Endo et al. , "A novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes. cDNA cloning and expression of leukotriene B4 omega-hydroxylase, " The Journal of Biological Chemistry, vol. 268, no. 13, pp. 9376-9380, 1993.
16. P. Christmas, S. R. Ursino, J. W. Fox, and R. J. Soberman, "Expression of the CYP4F3 gene. Tissue-specific splicing and alternative promoters generate high and low forms of leukotriene B4-hydroxylase, "The Journal of Biological Chemistry, vol. 274, no. 30, pp. 21191-21199, 1999.
17. P. Christmas, J. P. Jones, C. J. Patten et al. , "Alternative splicing determines the function of CYP4F3 by switching substrate specificity, " The Journal of Biological Chemistry, vol. 276, no. 41, pp. 38166-38172, 2001.
18. Y. Wang, J. Zhao, A. Kalsotra et al. , "CYP4Fs expression in rat brain correlates with changes in LTB4 levels after traumatic brain injury, " Journal of Neurotrauma, vol. 25, no. 10, pp. 1187-1194, 2008.
19. P. Christmas, N. Carlesso, H. Shang et al. , "Myeloid expression of cytochrome P450 4F3 is determined by a lineage-specific alternative promoter, "The Journal of Biological Chemistry, vol. 278, no. 27, pp. 25133-25142, 2003.
20. P. V. Afonso, M. Janka-Junttila, Y. J. Lee et al. , "LTB4 is a signalrelay molecule during neutrophil chemotaxis, " Developmental Cell, vol. 22, no. 5, pp. 1079-1091, 2012.
21. P. Christmas, K. Tolentino, V. Primo et al. , "Cytochrome P-450 4F18 is the leukotriene B4-1/-2 hydroxylase in mouse polymorphonuclear leukocytes: identification as the functional orthologue of human polymorphonuclear leukocyte CYP4F3A in the down-regulation of responses to LTB4, " The Journal of Biological Chemistry, vol. 281, no. 11, pp. 7189-7196, 2006.
22. V. Winslow, R. Vaivoda, A. Vasilyev et al. , "Altered leukotriene B4 metabolism in CYP4F18-deficient mice does not impact inflammation following renal ischemia, " Biochimica et Biophysica Acta, vol. 1841, no. 6, pp. 868-879, 2014.
23. N. S. A. Patel, S. Cuzzocrea, P. K. Chatterjee et al. , "Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton, " Molecular Pharmacology, vol. 66, no. 2, pp. 220-227, 2004.
24. L. Corcos, D. Le Lucas, C. Le Jossic-Corcos et al. , "Human cytochrome P450 4F3: structure, functions, and prospects, " Drug Metabolism and Drug Interactions, vol. 27, no. 2, pp. 63-71, 2012.
25. P. Christmas, "Role of cytochrome P450s in inflammation, " in Cytochrome P450 Function and Pharmacological Roles in Inflammation and Cancer, vol. 74 of Advances in Pharmacology, pp. 163-192, Elsevier, 2015.
26. D. J. Allendorf, J. Yan, G. D. Ross et al. , "C5a-mediated leukotriene B4-Amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-Tumor monoclonal antibody and-glucan, " Journal of Immunology, vol. 174, no. 11, pp. 7050-7056, 2005.
27. C. A. Rouzer, A. W. Ford-Hutchinson, H. E. Morton, and J. W. Gillard, "MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes, " The Journal of Biological Chemistry, vol. 265, no. 3, pp. 1436-1442, 1990.
28. K. Seno, T. Okuno, K. Nishi et al. , "Pyrrolidine inhibitors of human cytosolic phospholipase A2, " Journal of Medicinal Chemistry, vol. 43, no. 6, pp. 1041-1044, 2000.
29. W. T. Jackson, R. J. Boyd, L. L. Froelich, B. E. Mallett, and D. M. Gapinski, "Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982, "The Journal of Pharmacology and Experimental Therapeutics, vol. 263, no. 3, pp. 1009-1014, 1992.
30. E. D. Tomhave, R. M. Richardson, J. R. Didsbury, L. Menard, R. Snyderman, and H. Ali, "Cross-desensitization of receptors for peptide chemoattractants. Characterization of a new form of leukocyte regulation, " The Journal of Immunology, vol. 153, no. 7, pp. 3267-3275, 1994.
31. U. Jain, T. M. Woodruff, and A. Stadnyk, "The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10, " British Journal of Pharmacology, vol. 168, no. 2, pp. 488-501, 2013.
32. M. Alonso-Galicia, J. R. Falck, K. M. Reddy, and R. J. Roman, "20-HETE agonists and antagonists in the renal circulation, " American Journal of Physiology: Renal Physiology, vol. 277, no. 5, pp. F790-F796, 1999.
33. V. R. Holla, F. Adas, J. D. Imig et al. , "Alterations in the regulation of androgen-sensitive Cyp 4amonooxygenases cause hypertension, " Proceedings of the National Academy of Sciences of theUnited States of America, vol. 98, no. 9, pp. 5211-5216, 2001.